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CancerLiver receptor homolog-1 (NR5A2) is a nuclear receptor originally identiﬁed in the liver andmostly known for
its regulatory role in cholesterol and bile acid homeostasis. More recently, liver receptor homolog-1 has
emerged as a key regulator of intestinal function, coordinating unanticipated actions, such as cell renewal and
local immune function with important implications to common intestinal diseases, including colorectal
cancer and inﬂammatory bowel disease. Unlike most of the other nuclear receptors, liver receptor homolog-1
acts as a constitutively active transcription factor to drive the transcription of its target genes. Liver receptor
homolog-1 activity however is to a major extent regulated by different corepressors and posttranslational
modiﬁcations, which may account for its tissue-speciﬁc functions. This review will provide an update on the
molecular aspects of liver receptor homolog-1 action and focus on some emerging aspects of its function in
normal and diseased gut. This article is part of a Special Issue entitled: Translating nuclear receptors from
health to disease.slating nuclear receptors from
onjans).
lsevier B.V.© 2010 Published by Elsevier B.V.1. Introduction
Nuclear receptors represent one of the largest families of
transcription factors in mammals [1,2]. They control the expression
of genes implicated in reproduction, development and homeostasis.
The activity of most nuclear receptors is regulated by a diverse set of
lipid-soluble molecules, including steroid hormones, nutrients,
metabolites and endo/xenobiotics. The binding of these ligands to
nuclear receptors induces a conformational change leading to the
dissociation of corepressors and the recruitment of coactivators that
ultimately will result in the activation of downstream target genes
[3,4]. Nuclear receptors and their coregulators hence sense variations
in the intracellular concentration of hormones or metabolites and
subsequently elicit an adaptive response by modulating the expres-
sion of downstream target genes [5]. Although ligand-dependent
activity is a hallmark of the nuclear receptor family, somemembers do
not have an established physiological ligand or display constitutive
activity. These receptors are termed orphan nuclear receptors.
LRH-1 and its mammalian paralog, steroidogenic factor 1 (SF-1),
belong to the NR5A subgroup of nuclear receptors. Both nuclear
receptors bind as monomers to extended half sites in the promoter
region of their target genes and exhibit constitutive activity [6,7].
Crystallographic studies with recombinant mouse LRH-1 revealed
that the constitutive activity of LRH-1 can be ascribed to the
remarkable stable conformation of certain regions in the ligandbinding pocket that is associated with coactivator recruitment [8].
Even though several phospholipids have been found to bind LRH-1 in
vitro, it is not yet established whether they also act as physiological
ligands. In contrast, several corepressors are able to efﬁciently repress
the activity of LRH-1 by interacting with the ligand binding domain of
LRH-1, and several covalent modiﬁcations, including phosphorylation
and sumoylation, are known to modulate LRH-1 activity [9–17].
Since the initial discovery of LRH-1 in 1993 [18], major progress has
beenmade with regard to the understanding of its biological function.
Likemanynuclear receptors, LRH-1 exerts pleiotropic functions. LRH-1
is important in several aspects of life, ranging from the control of the
earliest events in development to cell speciﬁcation during differenti-
ation as well as of many other metabolic, immunoregulatory and
proliferative functions. In contrast to thewell established involvement
of LRH-1 in reverse cholesterol transport and bile acid metabolism in
the liver [11,19–29], more recent studies have identiﬁed LRH-1 as a
key player in the control of stem cell pluripotency [30–32] and
intestinal cell renewal [33]. This reviewwill focus on somenew studies
implicating LRH-1 as an essential transcriptional modulator in gut
function and in a number of gut-associated common diseases, such as
colorectal cancer (CRC) and inﬂammatory bowel disease (IBD).
2. The gut in health and disease
The gut is a highly organized structure that fulﬁlls many vital
functions in our body. Together with the skin, it represents one of the
largest surfaces of the human body. The epithelium of the gut plays an
essential role in nutrient, salt andwater absorption, and together with
the hepatocytes of the liver, it participates in the detoxiﬁcation and
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intestinal epithelium also establishes a selective barrier and provides
a ﬁrst line of defense against invading pathogens [34]. Interestingly,
the gut houses a large variety of commensal microorganisms, the gut
microbiota, which are intimately involved in several aspects of its
physiological functions [35]. This cohabitation, however, occurs
without eliciting the typical inﬂammatory responses observed after
infection, indicating that the intestinal tract has acquired complex
recognition systems that distinguish the beneﬁcial bacterial and
luminal antigens from the pathogenic ones. This immunotolerance is
severely compromised in patients with inﬂammatory bowel disease
(IBD), a chronic intestinal disorder that is characterized by inappro-
priate inﬂammatory responses to intestinal microbes [36]. In both
Crohn's disease and ulcerative colitis, the two major forms of IBD, a
disturbance in the balance between immune tolerance and defensive
inﬂammatory response constitutes the basis of the exacerbated
inﬂammation.
The mucosal layer is organized as a single layer of columnar
epithelial cells that is composed of several specialized cell types [37].
While the enterocytes are basically involved in the digestive and
absorptive functions of the gut, the goblet and Paneth cells provide
defenses against bacterial invasion through the production and
secretion of mucous, antimicrobial peptides and immunoregulatory
factors. Finally, the enteroendocrine cells provide a means of
communication with the body, by secreting peptide hormones that
inﬂuence diverse physiological processes.
As the intestinal epithelial cells are continuously exposed to a
harsh luminal environment, inﬂammation and tissue injury may
jeopardize cell integrity and normal intestinal function, often
observed in IBD patients. The epithelium, however, has an astonishing
capacity for self-renewal, and total renewal occurs every 4–5 days.
Intestinal self-renewal is driven by pluripotent stem cells that reside
in the proliferative crypt compartment, together with its uncommit-
ted progenitors [37,38]. After a limited number of divisions, the
progenitor cells differentiate into each of the specialized intestinal cell
types and migrate further up the crest of the villi, with the exception
of the Paneth cells that stably reside at the bottom of the crypts.
Once epithelial cells reach the top of the villi, they undergo apoptosis.
The ﬁnal status of the intestinal tract is hence the result of a dynamic
and tightly controlled process that involves the maintenance of a
delicate balance between proliferation, differentiation, migration and
cell death.
The canonical Wnt pathway is the primary signaling pathway that
stimulates proliferation and that coordinates the transition between
proliferation and differentiation of epithelial cells along the crypt/
villus axis. It consists of several components, with the β-catenin/TCF4
transcriptional complex being the main player that drives Wnt target
gene expression [39,40]. Similar to the proliferation gradient observed
in the crypts, the Wnt pathway is most active at the bottom and
gradually loses its activity when the cells move up to the villi,
indicating that an active pathway is essential for the maintenance of
uncommitted progenitor cells in the crypt compartment. This was
further conﬁrmed by the analysis of several loss- or gain-of-function
mouse models of single genes encoding various components of the
Wnt pathway and which exhibited impaired or exaggerated prolif-
eration, respectively [41–46].
Activating mutations in the Wnt pathway have been associated
with colorectal cancer (CRC), one of the most common cancers
worldwide [47]. Usually these mutations either inactivate the tumor
suppressor APC or activate the proto-oncogene β-catenin [48–51]. In
both cases, they result in the nuclear accumulation of β-catenin and
the transcriptional activation of its target genes. Mutations in theWnt
pathway are proposed to initiate the formation of benign adenomas,
the initial event in the adenoma–carcinoma sequence [50,52]. These
tumors can go unnoticed for several years. Only when additional
mutations arise, colorectal tumors become malignant.Both genetic and environmental factors trigger the development of
CRC. Chronic inﬂammation is an established environmental risk
factor. IBD patients are highly susceptible to develop colitis-associated
cancer (CAC), linked to the chronic damage of the colon and rectum
[53]. Both sporadic CRC and CAC tumors are to a major extent
inﬁltrated with various types of immune cells. In contrast to the
largely protumorigenic role of the immune cells in CAC tumors, the
immune inﬁltrates in sporadic as well as heritable CRC tumors may
also contribute to immunosurveillance, leading to the elimination of
transformed cells [54]. The mechanisms by which immune cells
impact on cancer initiation and progressionmay hence differ between
CAC and CRC.
3. Gut function and nuclear receptors
System-wide analysis of 39 mouse tissues indicated that a subset
of nuclear receptors is abundantly expressed in different areas of the
gastrointestinal tract [55]. Many of these nuclear receptors have been
earlier linked to regulatory functions in metabolic and/or immune
homeostasis of the gut. Some of these receptors are established
targets for the treatment of IBD, like the glucocorticoid receptor (GR)
or peroxisome proliferator-activated receptor γ (PPARγ) because of
the known therapeutic use in IBD of both corticosteroids and 5-
aminosalicylic acid (5-ASA), established activators of GR and PPARγ,
respectively [56–59].
More recently, nuclear receptors have beenmappedwith regard to
the crypt–villus axis in the distal ileum and proximal colon of both
normal and APCMin/+ mice [60]. APCMin/+ mice spontaneously
develop intestinal adenomas as a result of a point mutation in the
APC gene [61]. Interestingly, the nuclear receptor localization
signature established in this study allowed the authors not only to
predict the function of each receptor in the proliferation/differenti-
ation program but also to provide an alternative approach to screen
for nuclear receptors as potential targets to inhibit tumor develop-
ment and growth [60]. This work adds further value to earlier studies
describing functional interactions between single nuclear receptors
and the Wnt signaling pathway [62] and may be used as a basis to
identify additional roles for the nuclear receptor family in cell cycle
regulation, cancer and gut physiology in general. Based on these
studies, it is clear that nuclear receptors are well positioned to control
the normal and pathological functions of the gut. This review focuses
on one nuclear receptor, i.e. the liver receptor homolog-1 (LRH-1),
and its emerging role in gut development, physiology and patho-
physiology and highlights LRH-1 as an important transcriptional
mediator at the crossroads of developmental, metabolic and inﬂam-
matory pathways.
4. Molecular and physiological actions of LRH-1
Liver receptor homolog-1 (LRH-1, NR5A2), also known as pancreas
hormone receptor (PHR-1), fetoprotein transcription factor (FTF),
human B1-binding factor (hB1F) or CYP7A1 promoter binding factor
(CPF), belongs to the NR5A subfamily of nuclear receptors, which also
comprises the Drosophila fushi tarazu-factor 1 (Ftz-F1) and the
mammalian steroidogenic factor 1 (SF-1). All members of this
subfamily bind as monomers to extended nuclear receptor hexomeric
binding sites in the regulatory regions of their target genes. Speciﬁc
recognition of the 3 base pairs-long extension is ensured by the
conserved Ftz-F1 box, a stretch of about 26 amino acid residues,
located C-terminal from the DNA-binding domain [63]. For a long
time, members of the NR5A nuclear receptor subfamily have been
considered as receptors with constitutive transcriptional activity.
Some of these receptors, however, have been found to bind various
phospholipids, including phosphatidyl inositols (PI: PI(3,5)P2 and PI
(3,4,5)P3) [64–69], suggesting that these compounds could act as
natural ligands (Fig. 1). More recently, the SF-1 and LRH-1 ortholog in
Fig. 1. Regulation of LRH-1. LRH-1 activity can be regulated by several mechanisms, which involve transcriptional coregulators, posttranslational modiﬁcations (mainly
phosphorylation and sumoylation) and potentially phospholipid ligand binding (human LRH-1), although the latter mechanism is still not yet fully understood. Among the
coregulators, the corepressors SHP, DAX-1 and PROX-1 are particularly relevant to modulate the constitutive activity of LRH-1.
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containing long-chain fatty acids [70]. The enhanced intestinal fat
uptake and storage observed in long-chain acyl-CoA synthase (ACS-3)
mutant worms required NHR-25, and it was proposed that absence of
these long-chain fatty acid-containing PI lipids could account for this
effect, suggesting a functional link of PI and NHR-25 in C. elegans. It
will be of interest to determine the physiological relevance of these
molecules in mammalian systems.
Like most nuclear receptors, LRH-1 activity can also be
modulated by posttranslational events. Phosphorylation by ERK of
residues Ser-238 and Ser-243 of human LRH-1 enhances its
activation [13]. In the same study, p38MAPK was also suggested to
activate LRH-1, although to a lesser extent than ERK. Human LRH-1
is also phosphorylated by PKA at Ser-469 [9]. Interestingly, PKA-
mediated phosphorylation induces LRH-1-dependent steroidogene-
sis in breast cell lines [9], whereas it represses LRH-1-dependent
glucocorticoid production in an intestinal cell line [71], suggesting
that the effect of PKA on LRH-1 activity is cell type-dependent. LRH-
1 can also be sumoylated resulting in its translocation to
promyelocytic leukemia (PML) bodies in the nucleus and its
subsequent inactivation [10,72,73] (Fig. 1).
The high-afﬁnity interaction of LRH-1 with the atypical nuclear
receptor short heterodimer partner (SHP) has been well-deﬁned
[11,25,74,75]. Studies to demonstrate the physiological relevance of
the repressor function of SHP on LRH-1 activity were initially
performed in the context of the well established feedback inhibition
of bile acids on its own production. When bile acids levels build up in
the liver, SHP transcription is induced as a result of the activation of
farnesoid X receptor (FXR), the nuclear bile acid receptor. It was
demonstrated that an increase in SHP subsequently attenuates the
transcriptional activity of LRH-1, leading to the repression of LRH-1
targets, including the rate-limiting enzyme of the bile acid biosyn-
thesis pathway, cholesterol 7α-hydroxylase (CYP7A1) [11,25] and the
enzyme catalyzing the production of cholic acid, cholesterol 12α-
hydroxylase (CYP8B1) [20,76]. Analysis of liver-speciﬁc LRH-1
deﬁcient mice, however, revealed that this molecular paradigm of
feedback repression may not be as straightforward as initially
thought. Studies from our laboratory showed that LRH-1 in mouse
hepatocytes is not important for basal Cyp7a1 expression but in
contrast essential for the expression of Cyp8b1 and consequently for
bile acid composition [27]. Others have conﬁrmed these ﬁndings and
have shown that in addition LRH-1 is not essential for the FXR-
mediated feedback regulation of bile acid synthesis [24]. An important
question for the future will be to determine whether the lack of
difference in feedback regulation is the result of compensatory
mechanisms or whether LRH-1 is indeed dispensable in this
transcriptional network.LRH-1 also binds several other proteins that modulate its
transcriptional activity. Proteins such as multiprotein bridging
factor-1 (MBF1) [77]; steroid receptor coactivators (SRC)1, 2 and 3
[78] and peroxisome proliferator-activated receptor gamma coacti-
vator 1-alpha (PGC-1α) [79–81] bind and activate LRH-1-mediated
transcription. The corepressors dosage-sensitive sex-reversal–adrenal
hypoplasia congenita critical region on the X chromosome, gene 1
(Dax1) [67], prospero-related homeobox 1 (Prox-1) [14,16,82] and
PIASy [12] also bind LRH-1 and inactivate it (Fig. 1).
Besides an important role in development (discussed in the
section below), LRH-1 has emerged as a pleiotropic homeostatic
transcriptional regulator controlling aspects of metabolism, immune
function, cell proliferation and reproduction. The role of LRH-1 has
been best studied in the liver. Early studies focusing on target gene
identiﬁcation have positioned LRH-1 as a critical regulator of reverse
cholesterol transport, a process by which cholesterol is transported
from peripheral tissues by high density lipoproteins (HDL) to the liver
[21,22,26,29]. In addition, LRH-1 was also established as a crucial
regulator of bile acid homeostasis [11,19,20,23–25,27,28]. In the gut,
LRH-1 is most highly expressed in the proliferative cells residing in
the base of the crypts, and its expression is progressively lost as cells
differentiate and migrate towards the villi [33] (Fig. 3). This pattern of
expression mimics that of β-catenin [40], which is bound and
activated by LRH-1 [33]. Finally, the receptor is also expressed in
adipocyte precursors [83] and in steroidogenic tissues, including the
adrenal and the reproductive organs [84–86]. In the ovary, LRH-1 is
strongly enriched in the granulosa cells, where it regulates multiple
mechanisms essential for the maturation of ovarian follicles and for
ovulation, including the appropriate control of the hormonal balance
[87–89]. The importance of this discovery was underscored by the
observation that mice with a targeted mutation of the lrh-1 gene in
the granulosa compartment are infertile as a result of impaired
ovulation [88].
5. Developmental functions of LRH-1
LRH-1 is present from the early phases of embryo development. In
fact, it is highly expressed in embryonic stem cells (ES) [30,90], in all
cells in the morula stage (E2.5) and in the inner cell mass and
trophectoderm in the blastocyst stage (E3.5). At E5.5 (egg cylinder),
its expression becomes restricted to the visceral endoderm, while
ectodermal cells become negative for LRH-1. During gastrulation
(E6.5–E7.5), LRH-1 is still present in the endoderm and in the
primitive mesoderm. During mid-gestation (E8–E15), the receptor is
abundant in tissues derived from endoderm, such as liver, pancreas
and intestine, and in bone, testis and several brain regions [91,92].
Given its early developmental expression, it is not surprising that
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LRH-1 is robustly expressed in the liver, exocrine pancreas, ovary and
intestinal tract [18,55,90,92–94].
Several lines of evidence support a master role for LRH-1 in the
initial biological processes that govern stem cell pluripotency and
early development [30–32,95]. The ﬁrst target of LRH-1 identiﬁed in
this process was Oct4, a crucial pluripotency factor in embryonic
stem cells (ESC) [30]. Expressed in the pregastrulation embryo,
primordial germ cells and oocytes, Oct4 deﬁciency leads to
embryonic lethality at the blastocyst stage and to severe dysregula-
tion of the differentiation process in vitro [96]. Several nuclear
receptors bind to the Oct4 promoter and induce its expression at
different stages of development [97]. LRH-1 appears to be crucial for
its expression as Oct4 expression is lost at the epiblast stage in the
absence of LRH-1 [30]. In line with this study, others also identiﬁed
LRH-1, together with Oct4, Sox2 and ERRβ, as critical components of
a transcription factor regulatory network that maintains stem cell
pluripotency [30,95]. Interestingly, LRH-1 can also substitute for Oct4
during the reprogramming of induced pluripotent stem cells (iPS)
from mouse embryonic ﬁbroblasts (MEFs), further stressing its vital
role in the regulation of Oct4 and the establishment of pluripotency
[31]. A recent report suggests, however, that Oct4 is not the only
factor inﬂuenced by LRH-1 to maintain pluripotency in ESC [98].
Consistent with this observation, it was recently shown that LRH-1
also controls Nanog, another essential gene for embryo development
[32]. The canonical Wnt signaling triggers this LRH-1-mediated Oct4
and Nanog induction during early embryo development and
identiﬁes LRH-1 as a novel target of β-catenin and Tcf3 [32].
Accordingly, β-catenin deﬁciency also leads to embryonic lethality
at early embryonic stages (E6) [32]. DAX-1 is also abundantly
expressed in ESCs and has been identiﬁed as an interacting partner of
Nanog [95,99,100]. In view of the modulating role of DAX-1 on LRH-1
activity, it is tempting to speculate a possible functional interaction
between both nuclear receptors in ESCs, although this possibility still
requires further investigation.
Later during development, LRH-1 is involved in the embryonic
expression of a set of proteins essential for proper liver development.
In fact, LRH-1 controls the early expression of α-fetoprotein (AFP).
AFP is a marker of visceral endoderm and liver differentiation and is
expressed in endodermal cells that are freshly committed to the liver
lineage and its expression becomes extinct in the perinatal period
[90]. In addition, LRH-1 binds to the promoters and directs the
transcription of the hepatic nuclear factors HNF-1α, HNF-3β and HNF-
4α, which orchestrate embryonic liver development [92,101].
In combination these studies indicate that LRH-1 behaves as a
master regulator of a plethora of pathways during embryonic
development, ranging from the stem cell stage to the later phases of
development.
6. Role of LRH-1 in intestinal renewal and cancer
Renewal of the intestinal mucosa is triggered by stem cells
localized in the lower compartment of the crypts [37,38]. The
dividing cells become progenitor cells and the coordinated
expression of speciﬁc cell fate transcription factors, such as
Notch/RBP-J/Hes, Math1, Gﬁ1, Mtgr1, Klf4 and others [37], will
determine whether the progenitor cells will differentiate into
enterocytes, goblet cells or enteroendocrine cells, which all grad-
ually move towards the villi.
Consistent with its expression in intestinal crypts, we showed that
LRH-1 coordinates intestinal cell renewal [33] (Fig. 2). Expression of
LRH-1 by retroviral transduction was ﬁrst shown to promote cell
proliferation by enhancing cyclin-mediated G1/S transition of the cell
cycle. Two independent and complementary mechanisms account for
the effect of LRH-1 on cell cycle regulation. Consistent with its role as a
transcription factor, the ﬁrst mechanism involves the direct binding ofLRH-1 and subsequent activation of the cyclin E1 promoter, a process
stimulated by β-catenin, which binds LRH-1. The second mechanism
differs from the classic view by which LRH-1 controls target gene
expression and consists in the induction of cyclin D1 and c-Myc
transcription by β-catenin/Tcf4, a process in which LRH-1 acts as a
cofactor (Fig. 2). In the same study, LRH-1 also stimulates the
renewal of intestinal crypt cells in vivo, an effect that was attenuated
in LRH-1+/− mice. Altogether, these ﬁndings not only point to a role
for LRH-1 in cell cycle control, but they also extend the role of LRH-1
from a simple DNA-binding transcription factor to a coactivator via its
interaction with β-catenin. In a more recent study, the role of LRH-1
with regard to cell cycle control was analyzed [24]. Mice deﬁcient
for LRH-1 in the intestinal epithelium showed reduced cyclin E1 and
c-Myc mRNA levels but did not reveal any difference in the BrdU
proliferation index nor in cyclin D1 gene expression. The authors
concluded that this may reﬂect the additional requirement of other
cell types in the intestine to coordinate the proliferative response
of LRH-1.
Consistent with its role in intestinal cell renewal, LRH-1 also
modulates intestinal tumor formation in different cancer mouse
models [102]. LRH-1-haploinsufﬁciency signiﬁcantly inhibits intesti-
nal tumorigenesis both in the azoxymethane-induced intestinal
tumor model and in APCmin/+ mice [102]. Since β-catenin plays a
major role in the APCmin/+model, these results further underscore the
previously described β-catenin/LRH-1 relationship in intestinal cells
and its relevance in tumorigenesis.
One of the questions that remain to be answered is themodulation
of intestinal LRH-1 activity by its corepressors. Compared to the liver
and with the exception of the duodenum, only minute levels of SHP
are detected in the intestinal tract. This raises the question whether
LRH-1 acts alone or whether alternative corepressors, such as PROX-1
or DAX-1, replace SHP to ﬁne-tune LRH-1 activity in the intestine.
Further investigation will have to address the (patho)physiological
relevance of these potential interactions in vivo.
Apart from intestinal tumors, LRH-1 has also been associated to
several other types of cancer. LRH-1 acts as protumorigenic factor by
enhancing estradiol synthesis in preadipocytes, thus driving breast
cancer growth [103]. The LRH-1 gene locus has also been found to be
genetically associated with the development of exocrine pancreatic
cancer [104], although no functional study has yet been performed
addressing the potential role of LRH-1 in the development of this type
of cancer. LRH-1, along with SF-1, was also induced in endometrial
tumor cell lines where both NR5A family members enhance the
expression of the steroidogenic genes, steroidogenic acute regulatory
protein (star), 3b-hydroxysteroid dehydrogenase (3β-hsd) and
CYP19A1, leading to an increase in estradiol production, which is
considered one of the causes of endometrium tumors [105]. In the
liver, LRH-1 regulates the established tumor marker AFP, whose
expression is reinduced not only in hepatic but also in gastric cancers
[106,107]. In addition, LRH-1 induces the expression of the hepatitis B
virus [93], a leading cause of chronic hepatitis, often linked to the
development of hepatocellular carcinoma.
7. LRH-1 and inﬂammation: implications for inﬂammatory
bowel disease
Nuclear receptors in general, and LRH-1 in particular, have been
repeatedly associatedwith different inﬂammatory pathways [71,108–
111]. LRH-1 has been linked with two facets of the inﬂammatory
response. The ﬁrst one involves the control of the hepatic acute phase
response (APR), deﬁned as the host reaction in response to trauma,
infection, tissue damage or acute inﬂammation [112]. Part of this
response consists in the synthesis by hepatocytes of a set of proteins,
called acute phase response proteins (APP). LRH-1 negatively
regulates the expression of APPs [111,113], and this mechanism is
controlled by sumoylation of LRH-1 [114].
Fig. 2. LRH-1 drives cell cycle progression and tumorigenesis by synergizing with the β-catenin signaling pathway, acting directly as a transcription factor (cyclin E1) and as a
cofactor for Tcf-β-catenin (cyclin D1) in the gut. LRH-1 binds and activates the promoter of cyclin E1. β-catenin acts as a cofactor via interaction with LRH-1 to enhance LRH-1-driven
transcription of cyclin E1. In a similar fashion, but without direct binding to DNA, LRH-1 enhances β-catenin/Tcf4-driven transcription of another cell cycle promoter gene, cyclin D1.
Through these two mechanisms, LRH-1 pushes the cell cycle and favors tumor formation in different colorectal cancer models, the APCMin/+ (as depicted) and a chemically induced
model (AOM/DSS).
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involves the regulation of extra-adrenal glucocorticoid production
in gut. Initially, glucocorticoids production were thought to be
synthesized only in the adrenal glands and to perform its functions
systemically, transported by the circulatory system. Only recently,
this dogma has been revisited when several unexpected organs,
including the gut, were found to synthesize and secrete glucocorti-
coids in a paracrine fashion to regulate local immune cell
homeostasis [115]. The existence of extra-adrenal glucocorticoid
production in the intestine was initially established after injecting
mice an anti-CD3 antibody, which triggers T cell activation. This
strong immune challenge rapidly induced a counterregulatory
immune response in the intestinal epithelial cells consisting in a
strong induction of the steroidogenic cholesterol side-chain cleavage
enzyme P450scc (CYP11A1), which converts cholesterol to pregnen-
olone, and 11β-hydroxylase (CYP11B1), which catalyzes the con-
version of deoxycorticosterone into corticosterone (Fig. 3). Most
interesting with respect to this immune response was the observa-
tion that the induction of CYP11A1 and CYP11B1 was only limited to
the basal compartment of the intestinal mucosa [116], suggesting
that the induction requires crypt-enriched factors. In line with this
hypothesis, LRH-1, which is predominantly expressed in the
proliferating cells of the crypt compartment, was shown to be
essential for the local production of corticosterone via its regulation
of the steroidogenic enzymes CYP11A1 and CYP11B1 [71] (Fig. 3).
Corticosterone, which is the major glucocorticoid synthesized in
mice, acts as a potent inhibitor of inﬂammation through interference
with proinﬂammatory pathways activated by NF-kB and AP1 and
through activation of anti-inﬂammatory pathways. In view of these
well established actions, our laboratory has investigated the potential
relationship between LRH-1, intestinal corticosterone production and
susceptibility to dextran sodium sulfate (DSS) and 2,4,6-trinitroben-
zene sulfonic acid (TNBS)-induced colitis. Interestingly, the study
showed that both LRH-1 haploinsufﬁciency and somatic deﬁciency of
LRH-1 in the intestinal epithelium rendered mice more susceptible toexperimentally induced colitis [108]. In addition, the exacerbated
inﬂammation was associated with decreased local intestinal gluco-
corticoid production. Most importantly, analysis on IBD patients
revealed a signiﬁcant decrease in expression of LRH-1 and of its
transcriptional targets CYP11A1 and CYP11B1 in the affected tissues,
compared with healthy intestine [108], hence extending the role of
LRH-1 in experimental IBD mouse models to the human pathology.
Apart from their immunoregulatory action on local immune cells,
glucocorticoids may also induce intestinal tight junction proteins and
improve epithelial barrier function [117]. In addition, other functions
of LRH-1, such as its role in cell cycle progression, may contribute to
the protective phenotype on inﬂammation and associated epithelial
damage when LRH-1 levels are normal. In fact, it is plausible that after
hapten-induced mucosal inﬂammation, the cell cycle regulatory
function of LRH-1 comes into play to promote mucosal renewal
and regeneration. Another indication that cell cycle and glucocorti-
coids are closely linked via LRH-1 stems from the ﬁnding that
pharmacological inhibition of the cell cycle also strongly attenuates
LRH-1 activity and corticosterone synthesis in crypt cell-like
epithelial cells [118]. This effect likely explains why proliferating
crypt cells progressively lose CYP11A1 and CYP11B1 expression upon
differentiation.8. Discussion
The nuclear receptor LRH-1 constitutes a clear example of a
protein whose list of functions has gradually grown with time, to
include at present the control of a surprisingly wide set of
developmental and homeostatic pathways. This wide regulatory role
is further underscored by the recent addition of the control of
inﬂammation and cell proliferation as novel functions for this nuclear
receptor. LRH-1 controls these pathways in part through its regulatory
impact on steroidogenesis and via its cross talk with the β-catenin
signaling pathway.
Fig. 3. LRH-1 is highly expressed in the lower undifferentiated crypt compartment and directs anti-inﬂammatory corticosterone production in the intestinal crypts. The ﬁgure depicts
the intestinal epithelium, with the most undifferentiated cells—stem cells and progenitors—residing at the bottom of the crypts and the more differentiated enterocytes moving
towards the tip of the villi, where they ﬁnally undergo apoptosis and shedding. LRH-1 is enriched at the base of the crypts coinciding with markers of undifferentiated cells. LRH-1
levels drop as enterocytes undergo differentiation. Where it is expressed, LRH-1 regulates the synthesis of corticosterone, a potent anti-inﬂammatory glucocorticoid, by enhancing
the expression of the cytochrome p450 enzymes CYP11A1 and CYP11B1. Thus, LRH-1 plays a major role in the control of differentiation and inﬂammation, both of them crucial
processes in the development of IBD.
952 P.J. Fernandez-Marcos et al. / Biochimica et Biophysica Acta 1812 (2011) 947–955Since inﬂammation and proliferation are two mechanisms highly
relevant in the gut, it is not surprising that LRH-1 has emerged as a
crucial factor impacting on the development of inﬂammatory and
proliferative pathologies in this tissue. On the one hand, LRH-1
controls corticosterone-mediated regulation of the gut inﬂammatory
response. In line with this ﬁnding, LRH-1 ablation in the mouse
intestinal epithelium enhances inﬂammation, and IBD patients
coherently express lower levels of LRH-1 in the intestine [108].
Also, LRH-1 promotes proliferation of intestinal cells through its
ability to bind and enhance β-catenin-mediated transcription of pro-
proliferative genes such as cyclin E1, cyclin D1 and c-MYC. As a
consequence, intestines with only one functional allele for LRH-1
develop fewer tumors in different models of colorectal cancer [33].
The fact that LRH-1 reduces gut inﬂammation through corticoste-
rone production and, at the same time, enhances proliferation and
cancer may seem somehow contradictory since inﬂammation is
generally thought to favor tumor development [119]. Further
investigation is therefore required to elucidate this intriguing cross
talk between cell proliferation and anti-inﬂammatory responses that
is orchestrated by LRH-1. In particular, one should elucidate whether
pro-proliferative and anti-inﬂammatory actions are temporally and
spatially separated. For instance, tumor initiation could be driven by
the cell-autonomous effects of LRH-1 on cell proliferation, whereas
anti-inﬂammatory activities, that require cell-cell interactions, could
be more relevant during the later stages of tumorigenesis. Along the
same line, corticosterone production is conﬁned to the intestinal crypt
and it is currently unknown whether the steroidogenic enzymes are
expressed or alternatively can be reinduced in adenomas. If not, their
absence in adenomas would explain why the anti-inﬂammatory
properties of LRH-1 are not prevailing during tumorigenesis.
Taken together, LRH-1 has evolved to become a relevant player in
gut homeostasis over the last years. Modulating its activity through
the use of agonists [120] could therefore constitute an interesting
treatment option for pathologies in the gut and other tissues where
LRH-1 acts. In this regard, it is important to note that, whereas mouse
LRH-1 is constitutively active, synthetic agonists for LRH-1 have been
identiﬁed and shown to activate human LRH-1 [64,120]. In IBD
patients, with decreased expression of LRH-1, modulation of LRH-1
activity by synthetic agonists could prove to be a useful strategy tolimit chronic inﬂammation in the gut. As the anti-inﬂammatory effect
of LRH-1 is not dependent on glucocorticoid production in the adrenal
but on local synthesis in the intestinal crypts, synthetic agonists for
LRH-1 could provide a therapeutic strategy that avoids the negative
side effects of systemic glucocorticoids, often observed in patients
with IBD. The identiﬁcation and further development of small
molecules interfering with the interaction of the β-catenin/LRH-1
complex may constitute an even more challenging approach to
combat certain forms of colorectal cancer. Further studies will be
required to screen for these molecules and to examine the potential
impact on the progression of these different pathologies in different
models of IBD and colorectal cancer.
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